Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreot...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-12-01
|
Series: | Medical Devices : Evidence and Research |
Online Access: | http://www.dovepress.com/evaluation-of-long-acting-somatostatin-analog-injection-devices-by-nur-a11753 |
id |
doaj-9ecc58596e764d0f83610329d0c37beb |
---|---|
record_format |
Article |
spelling |
doaj-9ecc58596e764d0f83610329d0c37beb2020-11-24T21:04:28ZengDove Medical PressMedical Devices : Evidence and Research1179-14702012-12-012012default103109Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative studyAdelman DTBurgess ADavies PRDaphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed administering test injections with lanreotide-ND and octreotide long-acting release. The most important delivery system attributes were easy/convenient preparation and injection (ranked in the top five by 70% of nurses), low clogging risk (58%), and high product efficacy (55%). Compared with the octreotide long-acting release device, lanreotide-ND scored higher on 15/16 attributes, had shorter mean preparation and administration time (329 versus 66 seconds, respectively; P ≤ 0.01) and a higher overall preference score (70 versus 114, respectively; P ≤ 0.01). The five most important lanreotide-ND attributes were: prefilled device, confidence a full dose was delivered, low clogging risk, easy/convenient preparation and injection, and fast administration. These device features could lead to improvements in clinical practice and benefit patients/caregivers who administer SSAs at home.Keywords: nurse, somatostatin analog, device, lanreotide, octreotidehttp://www.dovepress.com/evaluation-of-long-acting-somatostatin-analog-injection-devices-by-nur-a11753 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Adelman DT Burgess A Davies PR |
spellingShingle |
Adelman DT Burgess A Davies PR Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study Medical Devices : Evidence and Research |
author_facet |
Adelman DT Burgess A Davies PR |
author_sort |
Adelman DT |
title |
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study |
title_short |
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study |
title_full |
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study |
title_fullStr |
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study |
title_full_unstemmed |
Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study |
title_sort |
evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study |
publisher |
Dove Medical Press |
series |
Medical Devices : Evidence and Research |
issn |
1179-1470 |
publishDate |
2012-12-01 |
description |
Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed administering test injections with lanreotide-ND and octreotide long-acting release. The most important delivery system attributes were easy/convenient preparation and injection (ranked in the top five by 70% of nurses), low clogging risk (58%), and high product efficacy (55%). Compared with the octreotide long-acting release device, lanreotide-ND scored higher on 15/16 attributes, had shorter mean preparation and administration time (329 versus 66 seconds, respectively; P ≤ 0.01) and a higher overall preference score (70 versus 114, respectively; P ≤ 0.01). The five most important lanreotide-ND attributes were: prefilled device, confidence a full dose was delivered, low clogging risk, easy/convenient preparation and injection, and fast administration. These device features could lead to improvements in clinical practice and benefit patients/caregivers who administer SSAs at home.Keywords: nurse, somatostatin analog, device, lanreotide, octreotide |
url |
http://www.dovepress.com/evaluation-of-long-acting-somatostatin-analog-injection-devices-by-nur-a11753 |
work_keys_str_mv |
AT adelmandt evaluationoflongactingsomatostatinanaloginjectiondevicesbynursesaquantitativestudy AT burgessa evaluationoflongactingsomatostatinanaloginjectiondevicesbynursesaquantitativestudy AT daviespr evaluationoflongactingsomatostatinanaloginjectiondevicesbynursesaquantitativestudy |
_version_ |
1716771043548332032 |